Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru
Mucormycosis has been reported increasingly in patients affected by COVID-19, especially in India where the first cases were described. In Latin America, there is limited information about this association, mainly coming from Brazil, Mexico, and Peru. Herein, we report the case of a 66-year-old fema...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2022/2537186 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551271824883712 |
|---|---|
| author | Linda Ponce-Rosas Jose Gonzales-Zamora Nelson Diaz-Reyes Oliver Alarco-Cadillo Jorge Alave-Rosas |
| author_facet | Linda Ponce-Rosas Jose Gonzales-Zamora Nelson Diaz-Reyes Oliver Alarco-Cadillo Jorge Alave-Rosas |
| author_sort | Linda Ponce-Rosas |
| collection | DOAJ |
| description | Mucormycosis has been reported increasingly in patients affected by COVID-19, especially in India where the first cases were described. In Latin America, there is limited information about this association, mainly coming from Brazil, Mexico, and Peru. Herein, we report the case of a 66-year-old female that presented with rhino-orbital-cerebral mucormycosis, diabetic ketoacidosis, and COVID-19. The patient had the compromise of all the sinuses, orbital invasion, and intracranial extension. Isavuconazole was promptly initiated because amphotericin B was not available. She had a single open surgical debridement of necrotic tissues at the beginning of the diagnosis then multiple manual sessions to clear the residual or recurrent disease during approximately 5 months. Isavuconazole was effective and well-tolerated for 10 months without side effects. We highlight the importance of considering mucormycosis in post-COVID-19 patients with uncontrolled diabetes. The report emphasizes the favorable outcome of isavuconazole as an alternative therapy. |
| format | Article |
| id | doaj-art-aab73453e47a4c058cf8d0e4a282f12e |
| institution | Kabale University |
| issn | 2090-6633 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Infectious Diseases |
| spelling | doaj-art-aab73453e47a4c058cf8d0e4a282f12e2025-02-03T06:01:53ZengWileyCase Reports in Infectious Diseases2090-66332022-01-01202210.1155/2022/2537186Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from PeruLinda Ponce-Rosas0Jose Gonzales-Zamora1Nelson Diaz-Reyes2Oliver Alarco-Cadillo3Jorge Alave-Rosas4Peruvian American Medical SocietyDepartment of MedicinePeruvian Union UniversityDepartment of Internal MedicinePeruvian Union UniversityMucormycosis has been reported increasingly in patients affected by COVID-19, especially in India where the first cases were described. In Latin America, there is limited information about this association, mainly coming from Brazil, Mexico, and Peru. Herein, we report the case of a 66-year-old female that presented with rhino-orbital-cerebral mucormycosis, diabetic ketoacidosis, and COVID-19. The patient had the compromise of all the sinuses, orbital invasion, and intracranial extension. Isavuconazole was promptly initiated because amphotericin B was not available. She had a single open surgical debridement of necrotic tissues at the beginning of the diagnosis then multiple manual sessions to clear the residual or recurrent disease during approximately 5 months. Isavuconazole was effective and well-tolerated for 10 months without side effects. We highlight the importance of considering mucormycosis in post-COVID-19 patients with uncontrolled diabetes. The report emphasizes the favorable outcome of isavuconazole as an alternative therapy.http://dx.doi.org/10.1155/2022/2537186 |
| spellingShingle | Linda Ponce-Rosas Jose Gonzales-Zamora Nelson Diaz-Reyes Oliver Alarco-Cadillo Jorge Alave-Rosas Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru Case Reports in Infectious Diseases |
| title | Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru |
| title_full | Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru |
| title_fullStr | Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru |
| title_full_unstemmed | Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru |
| title_short | Rhino-Orbital-Cerebral Mucormycosis in a Post-COVID-19 Patient from Peru |
| title_sort | rhino orbital cerebral mucormycosis in a post covid 19 patient from peru |
| url | http://dx.doi.org/10.1155/2022/2537186 |
| work_keys_str_mv | AT lindaponcerosas rhinoorbitalcerebralmucormycosisinapostcovid19patientfromperu AT josegonzaleszamora rhinoorbitalcerebralmucormycosisinapostcovid19patientfromperu AT nelsondiazreyes rhinoorbitalcerebralmucormycosisinapostcovid19patientfromperu AT oliveralarcocadillo rhinoorbitalcerebralmucormycosisinapostcovid19patientfromperu AT jorgealaverosas rhinoorbitalcerebralmucormycosisinapostcovid19patientfromperu |